VolitionRx (NYSE:VNRX) Research Coverage Started at StockNews.com

StockNews.com began coverage on shares of VolitionRx (NYSE:VNRX) in a research report released on Saturday. The firm issued a sell rating on the stock.

A number of other equities research analysts have also recently commented on the company. Benchmark reiterated a “hold” rating on shares of VolitionRx in a research note on Friday, November 22nd. D. Boral Capital reiterated a “buy” rating and issued a $5.00 price target on shares of VolitionRx in a research note on Thursday, February 6th.

VolitionRx Price Performance

Shares of NYSE VNRX opened at $0.58 on Friday. The business has a fifty day moving average price of $0.62 and a 200 day moving average price of $0.65. VolitionRx has a 1-year low of $0.43 and a 1-year high of $1.17. The stock has a market capitalization of $53.75 million, a P/E ratio of -1.61 and a beta of 1.20.

Insider Buying and Selling at VolitionRx

In other news, Director Guy Archibald Innes bought 174,764 shares of the firm’s stock in a transaction dated Monday, December 9th. The shares were acquired at an average price of $0.57 per share, for a total transaction of $99,615.48. Following the completion of the transaction, the director now directly owns 617,085 shares in the company, valued at $351,738.45. The trade was a 39.51 % increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Cameron John Reynolds bought 139,811 shares of the firm’s stock in a transaction dated Monday, December 9th. The stock was purchased at an average price of $0.57 per share, for a total transaction of $79,692.27. Following the transaction, the chief executive officer now owns 2,117,404 shares of the company’s stock, valued at approximately $1,206,920.28. This represents a 7.07 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last three months, insiders have acquired 358,266 shares of company stock valued at $204,212. Company insiders own 12.80% of the company’s stock.

Hedge Funds Weigh In On VolitionRx

An institutional investor recently raised its position in VolitionRx stock. Ground Swell Capital LLC increased its stake in shares of VolitionRx Limited (NYSE:VNRX) by 78.8% during the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 45,959 shares of the company’s stock after buying an additional 20,249 shares during the quarter. Ground Swell Capital LLC’s holdings in VolitionRx were worth $28,000 at the end of the most recent reporting period. 8.09% of the stock is owned by hedge funds and other institutional investors.

VolitionRx Company Profile

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.